骨質疏鬆症治療和骨折癒合市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球骨質疏鬆症治療和骨折癒合市場預計將從 2025 年的 153.4 億美元大幅成長至 2031 年的 199.7 億美元，複合年成長率為 4.49%。

該市場涵蓋專門用於維持骨骼密度和促進骨折癒合的藥物製劑和醫療設備。該市場的成長主要受全球人口老化及其導致的骨質疏鬆症和脆性骨折病例增加所驅動。此外，骨骼疾病日益沉重的經濟負擔也促使人們尋求有效的治療性介入，以降低長期醫療成本。例如，骨骼健康與骨質疏鬆基金會估計，到2030年，美國國內與骨質疏鬆性骨折相關的費用將超過950億美元。

然而，市場成長的主要限制因素是患者對骨吸收抑制劑治療的依從性低，這源於對罕見不利事件的擔憂。病人和醫護人員對這些啟動和繼續治療的顧慮造成了顯著的治療缺口，從而限制了現有治療方法的有效覆蓋範圍。因此，對於旨在最大限度提高市場滲透率並改善全球患者預後的利害關係人相關人員，克服治療推廣障礙仍然是一項至關重要的挑戰。

市場促進因素

市場的主要促進因素是全球人口老化和預期壽命延長，顯著擴大了骨質疏鬆風險族群。這些人口結構變化導致骨質流失和相關創傷的發生率上升，需要即時治療性介入和管理。這種人口壓力造成了沉重的臨床負擔，並增加了對診斷篩檢和預防醫學的需求。例如，國際骨質疏鬆基金會在2024年8月報告稱，全球每年發生多達3700萬例脆性骨折，凸顯了該問題的巨大規模。這些創傷造成的嚴重經濟和社會影響進一步迫使醫療保健系統解決治療方面的不平等問題。英國英國骨質疏鬆學會在2024年3月發布的聲明證實了這一點，該聲明指出，僅在英國，每年就有4200例可預防的股骨頸骨折是由於缺乏有效的骨折聯絡服務造成的。

第二個關鍵因素是新型促骨形成和抑制骨吸收治療方法的進步，為臨床醫生提供了更多管理高風險患者的有效選擇。製藥公司正大力投資生物製藥不僅能阻止骨吸收，還能促進新骨形成，進而為重度骨質疏鬆症患者帶來更佳療效。這項創新帶來了顯著的收入成長，凸顯了先進治療方法的商業性潛力。例如，安進公司2024年10月的財報顯示，Prolia當季銷售額年增6%，達10億美元。這些品牌療法的持續商業性成功表明，市場對安全性良好且能顯著改善骨骼密度的藥物有著強烈的偏好。

市場挑戰

全球骨質疏鬆症治療和骨折癒合市場擴張的最大障礙是患者依從性低這一長期存在的問題，這主要是由於對罕見不利事件的擔憂。儘管臨床證據顯示抗吸收療法可以降低骨折風險，但對顎骨壞死和非典型股骨骨折等潛在副作用的擔憂，使得患者和醫療服務提供者都猶豫不決。這種心理障礙不僅阻礙了必要的藥物治療的啟動，還導致高停藥率，從而影響製藥公司的收入來源，並限制了先進治療設備的應用。

這種被動式的治療方式造成了合格治療條件的患者群體與實際接受治療的患者群體之間存在顯著差距，直接限制了市場規模。由此產生的治療缺口導致大部分市場需求無法滿足，儘管骨骼疾病的盛行率不斷上升，但潛在的收入成長卻受到阻礙。這項未開發的市場機會規模龐大。根據國際骨質疏鬆症基金會（IOF）預測，到2025年，全球高達80%的脆性骨折患者預計將無法診斷和治療。這項數據凸顯了高盛行率未能轉化為永續的市場滲透率這一重大缺陷，從根本上損害了該行業的成長前景。

市場趨勢

隨著骨質疏鬆症主要生物製藥的生物相似藥的推出，尤其是重磅RANK配體抑制劑專利到期，市場正在經歷顯著的結構性變化。這一趨勢正在打破壟斷壁壘，加劇價格競爭，並大大改善患者獲得高效治療的機會，而這些治療先前由於價格昂貴，難以長期維持。這些更經濟實惠的替代療法的出現，迫使醫療系統擴大報銷範圍，從而增加了接受治療的患者人數。例如，2025年2月，《管理式醫療執行官》（Managed Healthcare Executive）報告稱，FDA已核准三星Bioepis公司的生物相似藥Ospomib和Xbryk用於治療骨質疏鬆症和骨轉移，這表明市場競爭加劇。這一系列監管核准不僅將降低醫療成本，還將迫使原廠藥生產商創新機制以維持市場佔有率。

同時，對非侵入性藥物遞送系統創新的高度重視，旨在應對患者對注射型合成代謝療法的抵觸情緒這一持續存在的挑戰。業內相關人員正在開發副甲狀腺素類似物的口服製劑，預計其療效將與皮下注射相當，同時顯著提高老年患者的依從性。這項進展解決了每日自行注射帶來的後勤和心理障礙，而這些障礙歷來是導致治療中斷率居高不下的原因。例如，Entera Bio公司於2025年9月發布的新聞稿公佈了其在ASBMR年會上發表的II期臨床試驗數據，結果顯示，口服PTH(1-34)片劑EB613在6個月後顯著提高了皮質骨參數，與現有注射製劑的效果相當。這些口服療法的成功商業化標誌著治療方法的一個重要轉折點，為治療重度骨質疏鬆症提供了一種便捷且以患者為中心的選擇。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：骨質疏鬆症治療與骨折癒合的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物類型（抑鈣素、雙磷酸鹽、荷爾蒙補充療法、合成代謝藥物、其他）
  • 給藥途徑（口服、注射）
  • 按通路分銷（醫院藥局、零售藥局、電子商務）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美骨質疏鬆症治療與骨折癒合市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲骨質疏鬆症治療與骨折癒合市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區骨質疏鬆症治療與骨折癒合市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲骨質疏鬆症治療和骨折癒合市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲骨質疏鬆症治療與骨折癒合市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球骨質疏鬆症治療與骨折癒合市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GlaxoSmithKline plc
• Medtronic Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Orthofix US LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for anti-osteoporosis therapy and fracture healing is projected to expand significantly, rising from USD 15.34 billion in 2025 to USD 19.97 billion by 2031, at a compound annual growth rate of 4.49%. This market encompasses pharmaceutical formulations and medical devices specifically designed to maintain bone density and accelerate the healing of skeletal fractures. Its expansion is largely fueled by the world's aging population and the resulting increase in osteopenia and fragility fractures. Furthermore, the growing financial burden of bone disorders mandates effective therapeutic interventions to alleviate long-term healthcare costs; for example, the Bone Health and Osteoporosis Foundation estimated that the national costs of osteoporotic fractures would exceed $95 billion by 2030.

Nevertheless, a key impediment to market growth is the high rate of patient nonadherence to antiresorptive therapies, often driven by worries about rare adverse events. This apprehension among patients and healthcare providers concerning starting or continuing treatment creates a substantial treatment gap, thereby limiting the effective reach of available therapies. Consequently, overcoming these barriers to treatment uptake remains a critical challenge for industry stakeholders aiming to maximize market penetration and enhance global patient outcomes.

Market Driver

The primary driver for the market is the rapidly aging global population and increased life expectancy, which significantly expands the patient demographic vulnerable to skeletal fragility. These demographic shifts lead to a higher incidence of low bone mass and related injuries, demanding immediate therapeutic interventions and management. This demographic pressure creates a substantial clinical burden, boosting demand for diagnostic screenings and preventive care; for instance, the International Osteoporosis Foundation reported in August 2024 that up to 37 million fragility fractures occur globally each year, highlighting the immense scale of the problem. The profound economic and social repercussions of these injuries further pressure healthcare systems to address the treatment gap, as evidenced by the Royal Osteoporosis Society's March 2024 statement indicating that the absence of effective fracture liaison services causes 4,200 preventable hip fractures annually in the UK alone.

A second crucial catalyst is the progress in novel anabolic and antiresorptive drug therapies, offering clinicians more powerful choices for managing high-risk patients. Pharmaceutical firms are heavily investing in biologics that not only prevent bone resorption but also encourage new bone formation, providing superior effectiveness for individuals with severe osteoporosis. This innovation translates into significant revenue growth and affirms the commercial potential of advanced treatments; for example, Amgen's October 2024 financial results showed a 6% year-over-year increase in Prolia sales, reaching $1.0 billion for the quarter. The sustained commercial success of such branded therapies underscores a strong market preference for agents that offer proven safety profiles and measurable improvements in bone mineral density.

Market Challenge

The foremost challenge impeding the expansion of the Global Anti Osteoporosis Therapy and Fracture Healing Market is the persistent issue of patient nonadherence, largely fueled by concerns over rare adverse events. Despite antiresorptive therapies being clinically proven to diminish fracture risks, apprehension regarding potential side effects, such as osteonecrosis of the jaw or atypical femoral fractures, creates significant reluctance among both patients and healthcare providers. This psychological barrier not only hinders the initiation of essential drug regimens but also results in high discontinuation rates, thus disrupting revenue streams for pharmaceutical manufacturers and restricting the adoption of advanced therapeutic devices.

This reluctance directly limits market volume by creating a vast disparity between the eligible patient population and those actually receiving treatment. The resulting treatment gap ensures that a large portion of the market remains underserved, stifling potential revenue growth despite the increasing prevalence of bone disorders. The scale of this unaddressed opportunity is substantial; according to the International Osteoporosis Foundation, in 2025, up to 80% of patients globally who experience a fragility fracture remain undiagnosed and untreated for the underlying condition. This statistic underscores a critical failure to translate high disease prevalence into sustained market engagement, thereby fundamentally undermining the industry's growth trajectory.

Market Trends

The market is undergoing a significant structural shift due to the introduction of biosimilars for major osteoporosis biologics, especially as patents for blockbuster RANK ligand inhibitors expire. This trend is breaking down exclusivity barriers, intensifying price competition, and considerably improving patient access to highly effective treatments that were previously too expensive for long-term management. The availability of these more affordable alternatives prompts healthcare systems to expand reimbursement criteria, consequently increasing the number of treated patients; for instance, Managed Healthcare Executive reported in February 2025 that the FDA approved Samsung Bioepis' biosimilars Ospomyv and Xbryk for osteoporosis and bone metastases, signaling heightened market rivalry. This series of regulatory approvals not only lowers healthcare costs but also compels originator companies to innovate new mechanisms to retain their market share.

Simultaneously, a strong focus on innovation in non-invasive drug delivery systems is addressing the ongoing challenge of patient reluctance towards injectable anabolic therapies. Industry participants are developing oral formulations of parathyroid hormone analogs, which are expected to offer efficacy similar to subcutaneous injections while substantially boosting adherence rates among older demographics. This development tackles both the logistical and psychological hurdles associated with daily self-injections, which have historically resulted in high discontinuation rates; for example, Entera Bio's September 2025 press release highlighted Phase 2 data from the ASBMR Annual Meeting, showing that the oral PTH(1-34) tablet EB613 achieved significant cortical bone parameter increases comparable to established injectable agents after six months. The successful commercialization of these oral options represents a crucial change in treatment approaches, providing a convenient, patient-centric choice for managing severe osteoporosis.

Key Market Players

• GlaxoSmithKline plc
• Medtronic Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Orthofix US LLC

Report Scope

In this report, the Global Anti Osteoporosis Therapy and Fracture Healing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti Osteoporosis Therapy and Fracture Healing Market, By Drug Type

• Calcitonin
• Bisphosphonates
• Hormone Replacement Therapy
• Anabolic
• Others

Anti Osteoporosis Therapy and Fracture Healing Market, By Route of Administration

• Oral
• Injectable

Anti Osteoporosis Therapy and Fracture Healing Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Anti Osteoporosis Therapy and Fracture Healing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti Osteoporosis Therapy and Fracture Healing Market.

Available Customizations:

Global Anti Osteoporosis Therapy and Fracture Healing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolic, Others)
  • 5.2.2. By Route of Administration (Oral, Injectable)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti Osteoporosis Therapy and Fracture Healing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GlaxoSmithKline plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Medtronic Plc.
• 15.3. Merck & Co. Inc.
• 15.4. Novartis AG
• 15.5. Pfizer inc.
• 15.6. Eli Lilly and Co.
• 15.7. F. Hoffmann-La Roche Ltd
• 15.8. Stryker Corporation
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Orthofix US LLC

16. Strategic Recommendations

17. About Us & Disclaimer